View in EDS

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
Authors: Yuan J; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Gong J; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Peng Z; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China., Liu TS; Medical Oncology Department, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China., Xu H; Oncology Department, Hubei Cancer Hospital, Wuhan, China., Yang J; Clinical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China., Wei J; Oncology Department, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China., Jiang H; Medicine Department, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China., Deng Y; Clinical Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Wang Y; Gastroenterology Ward One Department, Shanxi Cancer Hospital, Taiyuan, China., Qi C; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, China., Lyu C; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Sun Q; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Mu L; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Song L; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China., Zhang X; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. zhangxiaotian@bjmu.edu.cn., Shen L; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. shenlin@bjmu.edu.cn.
Source: British journal of cancer [Br J Cancer] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42337043
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yuan+J%22">Yuan J</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Gong+J%22">Gong J</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Peng+Z%22">Peng Z</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Liu+TS%22">Liu TS</searchLink>; Medical Oncology Department, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Xu+H%22">Xu H</searchLink>; Oncology Department, Hubei Cancer Hospital, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Yang+J%22">Yang J</searchLink>; Clinical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Wei+J%22">Wei J</searchLink>; Oncology Department, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Jiang+H%22">Jiang H</searchLink>; Medicine Department, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Deng+Y%22">Deng Y</searchLink>; Clinical Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Gastroenterology Ward One Department, Shanxi Cancer Hospital, Taiyuan, China.<br /><searchLink fieldCode="AU" term="%22Qi+C%22">Qi C</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Lyu+C%22">Lyu C</searchLink>; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Sun+Q%22">Sun Q</searchLink>; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Mu+L%22">Mu L</searchLink>; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Song+L%22">Song L</searchLink>; Clinical Development, Shanghai LianBio Development Co. Ltd., Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. zhangxiaotian@bjmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Shen+L%22">Shen L</searchLink>; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China. shenlin@bjmu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2026 Jun 23. <i>Date of Electronic Publication: </i>2026 Jun 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42337043
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-026-03511-0
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yuan J
      – PersonEntity:
          Name:
            NameFull: Gong J
      – PersonEntity:
          Name:
            NameFull: Peng Z
      – PersonEntity:
          Name:
            NameFull: Liu TS
      – PersonEntity:
          Name:
            NameFull: Xu H
      – PersonEntity:
          Name:
            NameFull: Yang J
      – PersonEntity:
          Name:
            NameFull: Wei J
      – PersonEntity:
          Name:
            NameFull: Jiang H
      – PersonEntity:
          Name:
            NameFull: Deng Y
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Qi C
      – PersonEntity:
          Name:
            NameFull: Lyu C
      – PersonEntity:
          Name:
            NameFull: Sun Q
      – PersonEntity:
          Name:
            NameFull: Mu L
      – PersonEntity:
          Name:
            NameFull: Song L
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Shen L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 06
              Text: 2026 Jun 23
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1